CEO: Maarten de Chateau
Description: Sixera Pharma is a biopharmaceutical company with expertise in dermatology, and especially rare genetic skin diseases (genodermatoses). We are focusing our drug development effort on protease biology in the skin and have developed a series of compounds targeting certain skin proteases (kallikreins) known to cause a rare inherited skin disease called Netherton’s syndrome. The lead compound is currently undergoing IND enabling studies.
CEO: Johan Sandin
CEO: Annsofi Nihlén
Description: PKxpert AB provides consultancy services & scientific expert knowledge to pharmaceutical companies in
- Pharmacokinetic and Toxicokinetic analysis in non-clinical and clinical studies using Phoenix WinNonlin®
- Toxicokinetic analysis according to GLP
- Pharmacokinetic simulations and predictions for study design
- Drug metabolism & regulatory ADME studies
- Compiling of regulatory non-clinical documentation in CTD format
- Preclinical research & development project management
- Quality assurance according to GxP
PKxpert staff has extensive experience from big pharma and biotech companies with small molecules, peptides, proteins and monoclonal antibodies.
CEO: Lech Ignatowicz
Biopromic is working to change the future of rapid, point-of-care diagnostics for the detection of infectious diseases. A spectrum of Biopromic’s proprietary technologies allows for the development of simple-to-use and affordable tests for clinical and veterinary settings. Biopromic specializes in the production of ultra-sensitive monoclonal antibodies targeted primarily against carbohydrate antigens derived from bacteria and viruses. Biopromic also produces a wide range of bacterial antigens and their analogs. Biopromic is a privately held company established in 2006 in Poland. In 2017, Biopromic opened its new R&D facility at Karolinska Institutet Science Park in Stockholm, Sweden.
COO: Johan Itzel
Description: ObsteCare offers a method and instruments for monitoring the mother during delivery. By measuring the lactate levels in the amniotic fluid during a delivery you can assess the status and understand the risk of a prolonged delivery. Labor dystocia is the most common problem in maternity wards and roughly 40% of first-time mothers are affected. Labor dystocia causes suffering for mother and child alike and is the source for a number of disorders for women later in life, decreasing women’s quality of life and putting pressure on the welfare system. ObsteCare’s AFLTM gives doctors the tools and methods for diagnosing labor dystocia and a method for improving the treatment. The method is based on international scientific research and has been patented.
CEO: Christian Cammin
Director Scandinavia: Paola Longati
Description: GeneConsult is a specialist sales company in medical genetic diagnostics. We partner with high quality companies to promote their products & services through our network of medical professionals across Northern Europe. Our team consists of highly educated professionals with over 20 years’ experience in genetic diagnostics, business development and sales, with an in-depth knowledge of scientific and diagnostic developments. We are committed to creating a transparent work environment for our partners, our network and ourselves to build solid, trustful and long-term relationships.
CEO: Pavankumar Asalapuram
Description: ApiRays® has developed a recombinant apyrase enzyme called ApiOne® from bacterial origin that can instantly eliminate ATP, ATP by-products and ATP analogues. Using ApiOne® in ATP-based diagnostics, it is possible to improve the sensitivity of diagnostic and analytical tests, including ATP-based bioluminescence and colorimetric tests. The uniqueness of ApiOne® can be extend to applications in biomedicine, food and beverages, drug discovery and pharmaceutical industries. ApiOne® provides significant advantages for the DNA sequencing industry, especially Pyrosequencing as it can increase the DNA read-lengths by at least 20%. Our patented solutions not only provide a superior alternative to potato apyrase but could also reduce the experimental turn-around time up to 40%, thus reducing costs.
CEO Janssen, Nordic: Lars Johansson
Web: www.janssen.com/sweden and www.janssen.com
About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on www.twitter.com/janssenEMEA for our latest news.